Covance Expands Global Biologics Capabilities
Covance announced it is expanding its large molecule bioanalytical space
Covance announced it is expanding its large molecule bioanalytical space co-located with Covance’s central laboratory facility in Indianapolis, IN to grow its global biologics capabilities. The expansion, which is planned to open during the second half of 2014, is doubling the company’s large molecule capacity. With this expansion, Covance expects to add 100 new positions over the next five years. This investment will enable Covance to further leverage its small and large molecule bioanalytical expertise while providing scientific, logistic, and regulatory synergies for clients.
Read the full release here.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
